In vitro methods Sample Clauses

In vitro methods. When performing risk assessment mostly based on in vitro test results, in vitro to in vivo extrapolation (IVIVE) shall be performed. One of the essential aspects of IVIVE is kinetic information. In vitro tests generally do not consider the kinetics of a body as animal tests do: the absorption in the gut, for example, is not considered in an in vitro test with liver cells. Thus, in vitro test results must be supplemented with kinetic data using kinetic models to enable IVIVE. This approach is valid for non-nano (molecular) substances and there is no reason why this general approach should not be valid for NMs as well. Some NMs can dissolve into the molecular or ionic form. As a result, such NMs essentially lose their nanoparticle properties and can be dealt with using the same approach applied to the non- nano (molecular) substances. For the NMs that do not dissolve (and are thus durable), there is a high potential for accumulation as no other elimination pathways are currently known besides dissolution. In case of accumulation of molecular substances and NMs, the accurate determination of the kinetics becomes of greater importance for the correct estimation of human health risk as an extrapolation over time needs to be made. Even though kinetic information in general is just as important for molecular substances as for NMs, the type of kinetic information that is necessary differs (Table 3.8). Available kinetic studies generally demonstrate a distribution pattern for nanoparticles that differs from molecular substances. Particles tend to disappear from the blood very rapidly and distribute to liver, spleen, and to a lesser extent to lung and testis (x.x. Xxxxxxx et al. 2014, van Xxxxxxxx et al. 2014). It is remarked that comparisons between molecular substances and nanoforms are not always possible as some of the most widely used nanoparticles are not available in molecular form. A few PBPK- models23 for nanoparticles have been published based on the paradigm that the distribution is not a diffusion-driven process (as for most organic molecular substances) but a process governed by the active uptake of the nanoparticles by macrophages (x.x. Xxxxxxx et al. 2015, Xxxxxxxxx et al. 2016, Xxx et al. 2016). This implies that sampling plasma is not suitable to monitor nanoparticle exposure and kinetics. Kinetic parameters important for IVIVE with NMs are: • Dissolution rate in the various surroundings (including in macrophages); • Protein corona composition and s...
Sample 1
AutoNDA by SimpleDocs

Related to In vitro methods

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Treatment Program Testing The Employer may request or require an employee to undergo drug and alcohol testing if the employee has been referred by the employer for chemical dependency treatment or evaluation or is participating in a chemical dependency treatment program under an employee benefit plan, in which case the employee may be requested or required to undergo drug or alcohol testing without prior notice during the evaluation or treatment period and for a period of up to two years following completion of any prescribed chemical dependency treatment program.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • SHOP DRAWINGS, PRODUCT DATA AND SAMPLES 4.12.1 Shop Drawings are drawings, diagrams, schedules and other, data specially prepared for the Work by the Contractor or any Subcontractor, manufacturer, supplier or distributor to illustrate some portion of the Work.

  • Program Components Activities and services delivered under this Program Element align with Foundational Programs and Foundational Capabilities, as defined in Oregon’s Public Health Modernization Manual, (xxxx://xxx.xxxxxx.xxx/oha/PH/ABOUT/TASKFORCE/Documents/public_health_modernization_man ual.pdf) as well as with public health accountability outcome and process metrics (if applicable) as follows:

  • COVID-19 Protocols Contractor will abide by all applicable COVID-19 protocols set forth in the District’s Reopening and COVID-19 Mitigation Plan and the safety guidelines for COVID-19 prevention established by the California Department of Public Health and the Ventura County Department of Public Health.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

Time is Money Join Law Insider Premium to draft better contracts faster.